Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35254922.
- Also identified by DOI 10.1200/OP.21.00890.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The shortage of dacarbazine (DTIC) has created an acute and unprecedented crisis in the management of patients with classical Hodgkin lymphoma, with DTIC being an essential component of doxorubicin, bleomycin, vinblastine, and DTIC (ABVD) and prior attempts at omitting DTIC from ABVD leading to substantial loss of efficacy. In this review, we discuss the strategies to manage classical Hodgkin lymphoma during the DTIC shortage and propose a treatment algorithm on the basis of fitness and ability to receive anthracyclines safely.
Medical subject headings
- Hodgkin Disease